Antimicrobial PK in Infants With Suspected or Confirmed Infection

Official Title: “Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study)”

The purpose of this protocol is to provide a mechanism for the ongoing collection of blood and urine samples in newborns that will be used to measure levels of antimicrobial products used in the newborn population where there are limited pharmacokinetic data in either premature or term infants.

Greater than 90% of infants born <32 weeks admitted to critical care nurseries are treated with antimicrobial agents during their NICU hospitalization. Most antimicrobial products used in the neonatal population lack some aspect of pharmacokinetic information specific to neonates. Dosing is based largely on pharmacokinetic data from older children or in some cases, adults. This study will also establish a bank of urine samples from newborns treated with antimicrobial and/or antifungal therapy and to characterize the urinary proteome in selected samples. The sites of the NIH-sponsored Pediatric Pharmacology Research Network (PPRU) have access to appropriate assays using microliter amounts of serum and a large pool of potential subjects to generate meaningful data that will

1. Guide dosing of commonly used antimicrobial agents, and

2. Provide preliminary data for future industry and government trials in the nursery.

Intervention(s) in this Clinical Trial

• Drug: Ampicillin
  • Drug prescribed per routine medical care.
• Drug: Metronidazole
  • Drug prescribed per routine medical care.
• Drug: Piperacillin/Tazobactam
  • Drug prescribed per routine medical care.
• Drug: Acyclovir
  • Drug prescribed per routine medical care.
• Drug: Amphotericin B
  • Drug prescribed per routine medical care.
• Drug: Ambisome
  • Drug prescribed per routine medical care.
• Drug: Anidulafungin
  • Drug prescribed per routine medical care.
• Drug: Caspofungin
  • Drug prescribed per routine medical care.

Arms, Groups and Cohorts in this Clinical Trial

• : <26 weeks
  • Subjects <26 weeks gestational age
• : 26-29 weeks
  • Subjects 26-29 weeks gestational age
• : 30-32 weeks
  • Subjects 30-32 weeks gestational age

Inclusion Criteria:

• Infants ≤32 weeks and 6 days EGA with high probability of receiving one of the antimicrobial agents listed are eligible for study.
• Age younger than 120 days
• Written informed consent from parent or legal guardian
• Infants likely to survive beyond 48 hours after enrollment

Exclusion Criteria:

• Failure to consent

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: 120 Days

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Duke University Other

Overall Clinical Trial Officials and Contacts

Danny Benjamin, MD Principal Investigator PPRU  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00491426

Study ID Number: PPRU 10824

ClinicalTrials.gov Identifier: NCT00491426

Health Authority: United States: Federal Government